Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M, Hiyoshi T, Inoue I, Iso K, Yoshii H, Hirose T, Kumashiro N. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovasc Diabetol. 2020 Jan 7;19(1):1.
Hatano M, Inoue I, Kurihara S, Ono H, Matsuda M, Kakei M, Inukai T, Aso Y, Katayama S. Long-Term Efficacy and Safety of Add-On Therapy of Sitagliptin to a Very Small Dose of Glimepiride Versus a Small Dose of Glimepiride Over Eighteen Months. J Endocrinol Metab. 2019 Dec;9(6):171-179.
Sakai N, Fuchigami H, Ishizuka T, Tanaka T, Kato M, Nakamura T, Nakayama K, Kawaguchi R, Kuroda Y, Munakata H, Noda M, Kakei M, Matsumoto M. Relationship between a Urine Protein-to-creatinine Ratio of 150 mg/gram Creatinine and Dipstick Grade in the Health Checkup: Substantial Number of False-negative Results for Chronic Kidney Disease. Tokai J Exp Clin Med. 2019 Dec 20;44(4):118-123.
Kashino I, Serafini M, Kurotani K, Akter S, Mizoue T, Ishihara J, Kotemori A, Sawada N, Inoue M, Iwasaki M, Noda M, Tsugane S; Japan Public Health Center-based Prospective Study Group. Relationship between dietary non-enzymatic antioxidant capacity and type 2 diabetes risk in the Japan Public Health Center-based Prospective Study. Nutrition. 2019 Oct;66:62-69.
Oikawa Y, Sakamoto K, Satomura A, Haisa A, Katsuki T, Hattori Y, Inoue I, Noda M, Shimada A. Significance of peripheral mononuclear cells producing interferon-γ in response to insulin B:9–23-related peptides in subtypes of type 1 diabetes. Clin Immunol. 2019 Nov;208:108260.
Kashino I, Mizoue T, Serafini M, Akter S, Sawada N, Ishihara J, Kotemori A, Inoue M, Yamaji T, Goto A, Iwasaki M, Noda M, Tsugane S; Japan Public Health Center-based Prospective Study Group. Higher Dietary Non-enzymatic Antioxidant Capacity Is Associated with Decreased Risk of All-Cause and Cardiovascular Disease Mortality in Japanese Adults. J Nutr. 2019 Sep 9:nxz145.
Hatano M, Mimura T, Shimada A, Noda M, Katayama S. Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency. Endocrinology, Diabetes & Metabolism. 2019 May 9;2(3):e00071.
Nakamura Y, Nagai Y, Kobayashi T, Furukawa K, Oikawa Y, Shimada A, Tanaka Y. Characteristics of Gut Microbiota in Patients With Diabetes Determined by Data Mining Analysis of Terminal Restriction Fragment Length Polymorphisms. J Clin Med Res. 2019 Jun;11(6):401-406.
Katanoda K, Noda M, Goto A, Mizunuma H, Lee JS, Hayashi K. Being underweight in adolescence is independently associated with adult-onset diabetes among women: The Japan Nurses’ Health Study. J Diabetes Investig. 2019 May;10(3):827-836.
Nakashima N, Noda M, Ueki K, Koga T, Hayashi M, Yamazaki K, Nakagami T, Ohara M, Gochi A, Matsumura Y, Kimura M, Ohe K, Kang D, Toya Y, Yamagata K, Yokote K, Ikeda S, Mitsutake N, Yamamoto R, Tanizawa Y. Recommended configuration for personal health records by standardized data item sets for diabetes mellitus and associated chronic diseases: A report from Collaborative Initiative by six Japanese Associations. J Diabetes Investig. 2019 May;10(3):868-875.
Chen S, Akter S, Kuwahara K, Matsushita Y, Nakagawa T, Konishi M, Honda T, Yamamoto S, Hayashi T, Noda M, Mizoue T. Serum amino acid profiles and risk of type 2 diabetes among Japanese adults in the Hitachi Health Study. Sci Rep. 2019 May 7;9(1):7010.
Sakane N, Kotani K, Suganuma A, Takahashi K, Sato J, Suzuki S, Izumi K, Kato M, Noda M, Nirengi S, Kuzuya H. Prevention of Metabolic Syndrome by Telephone-Delivered Lifestyle Intervention in a Real-World Setting: Sub-Analysis of a Cluster-Randomized Trial. Metab Syndr Relat Disord. 2019 Sep;17(7):355-361.
Nakashima N, Noda M, Ueki K, Koga T, Hayashi M, Yamazaki K, Nakagami T, Ohara M, Gochi A, Matsumura Y, Kimura M, Ohe K, Kang D, Toya Y, Yamagata K, Yokote K, Ikeda S, Mitsutake N, Yamamoto R, Tanizawa Y. Recommended configuration for personal health records by standardized data item sets for diabetes mellitus and associated chronic diseases: a report from a collaborative initiative by six Japanese associations. Diabetol Int. 2019 Apr 25;10(2):85-92.
Goto A, Yamaji T, Sawada N, Momozawa Y, Kamatani Y, Kubo M, Shimazu T, Inoue M, Noda M, Tsugane S, Iwasaki M. Diabetes and cancer risk: A Mendelian randomization study. Int J Cancer. 2020 Feb 1;146(3):712-719.
Oikawa Y, Kondo T, Shimada A, Seino Y, Kitaoka M: Actual condition survey regarding mismatch of measurements between radioimmunoassay and enzyme-linked immunosorbent assay tests for anti-glutamic acid decarboxylase antibody in real-world clinical practice. J Diabetes Investig. 2019 May;10(3):685-689.
Saito D, Oikawa Y, Yano Y, Ikegami Y, Satomura A, Isshiki M, Kurihara S, Inoue I, Noda M, Shimada A. Detailed Time Course of Decline in Serum C-Peptide Levels in Anti-Programmed Cell Death-1 Therapy-Induced Fulminant Type 1 Diabetes. Diabetes Care. 2019 Mar;42(3):e40-e41.
Saito D, Oikawa Y, Mizutani G, Inoue K, Hatano M, Inoue I, Noda M, Shimada A. Clinical characteristics of anti-glutamic acid decarboxylase antibody-positive fulminant type 1 diabetes. Endocr J. 2019 Apr 25;66(4):329-336.
Nakano T, Inoue I, Murakoshi T. A Newly Integrated Model for Intestinal Cholesterol Absorption and Efflux Reappraises How Plant Sterol Intake Reduces Circulating Cholesterol Levels. Nutrients. 2019 Feb 1;11(2). pii: E310.
Yasuda S, Iuchi T, Goto A, Katanoda K, Iida S, Oikawa Y, Namba A, Isshiki M, Inoue I, Kamei Y, Shimada A, Noda M. Weight control before and during pregnancy for patients with gestational diabetes mellitus. J Diabetes Investig. 2019 Jul;10(4):1075-1082.
Hidaka A, Budhathoki S, Yamaji T, Sawada N, Tanaka-Mizuno S, Kuchiba A, Charvat H, Goto A, Shimazu T, Inoue M, Noda M, Tsugane S, Iwasaki M; JPHC Study Group. Plasma C-peptide and glycated albumin and subsequent risk of cancer: From a large prospective case-cohort study in Japan. Int J Cancer. 2019 Feb 15;144(4):718-729.
Nanri A, Mizoue T, Noda M, Goto A, Sawada N, Tsugane S; Japan Public Health Center-based Prospective Study (JPHC Study) Group. Menstrual and reproductive factors and type 2 diabetes risk: The Japan Public Health Center-based Prospective Study. J Diabetes Investig. 2019 Jan;10(1):147-153.
Kawabata Y, Nishida N, Awata T, Kawasaki E, Imagawa A, Shimada A, Osawa H, Tanaka S, Takahashi K, Nagata M, Yasuda H, Uchigata Y, Kajio H, Makino H, Yasuda K, Kobayashi T, Hanafusa T, Tokunaga K, Ikegami H. Genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying Variants in CSAD/lnc-ITGB7-1 on Chromosome 12q13.13 Associated with Susceptibility to Fulminant Type 1 Diabetes. 2019 Mar;68(3):665-675.
Nishimoto M, Ohtsu H, Marumo T, Kawarazaki W, Ayuzawa N, Ueda K, Hirohama D, Kawakami-Mori F, Shibata S, Nagase M, Isshiki M, Oba S, Shimosawa T, Fujita T. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study. Hypertens Res. 2019 Apr;42(4):514-521.
Takita M, Jimbo E, Fukui T, Aida K, Shimada A, Oikawa Y, Yagihashi S, Miura J, Babazono T, Kobayashi T. Unique Inflammatory Changes in Exocrine and Endocrine Pancreas in Enterovirus-induced Fulminant Type 1 Diabetes. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4282-429.
Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y, Oikawa Y, Osawa H, Kajio H, Kawasaki E, Kawabata Y, Kozawa J, Shimada A, Takahashi K, Tanaka S, Chujo D, Fukui T, Miura J, Yasuda K, Yasuda H, Kobayashi T, Hanafusa T; consultation of the Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2019 Jan;10(1):58-66.
Mizutani G, Hikima Y, Satomura A, Iuchi T, Nakajima R, Miyashita Y, Yasuda S, Oikawa Y, Isshiki M, Inoue I, Noda M, Shimada A: Administration of thiamazole for Graves’ disease might trigger the onset of type 1 diabetes. J Diabetes Investig 9:1228-1229,2018
Sakai G, Saito D, Nakajima R, Hatano M, Noguchi Y, Kurihara S, Katayama S, Inoue I, Noda M, Shimada A: Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in ‘anti-programmed cell death protein 1 antibody-induced’ fulminant type 1 diabetes. J Diabetes Investig 9:448-449,2018
Shimada A, Hanafusa T, Yasui A, Lee G, Taneda Y, Sarashina A, Shiki K, George J, Soleymanlou N, Marquard J: Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial. Diabetes Obes Metab 20:2190-2199,2018
Ikegami Y, Inoue I, Inoue K, Shinoda Y, Iida S, Goto S, Nakano T, Shimada A, Noda M: The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. NPJ Aging Mech Dis 4:7,2018
Ito D, Inoue K, Sumita T, Hamaguchi K, Kaneko K, Yanagisawa M, Inukai K, Inoue I, Noda M, Shimada A: Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study. J Clin Med Res 10:679-687, 2018